BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22278034)

  • 1. [Demethylating medication in myelodysplastic syndrome].
    Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
    Lübbert M
    Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
    [No Abstract]   [Full Text] [Related]  

  • 3. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug therapy for myelodysplastic syndrome: building evidence for action.
    Tefferi A; Letendre L
    Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting DNA methylation.
    Issa JP; Kantarjian HM
    Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplasia, megakaryocytes, and methylation.
    Steensma DP
    Leuk Res; 2004 Aug; 28(8):775-6. PubMed ID: 15203274
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].
    Gao Y; Ping B; Zhou S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Feb; 32(2):280-2. PubMed ID: 22381778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review: recent clinical trials in epigenetic therapy.
    Oki Y; Issa JP
    Rev Recent Clin Trials; 2006 May; 1(2):169-82. PubMed ID: 18473969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).
    Silverman LR
    Oncologist; 2001; 6 Suppl 5():8-14. PubMed ID: 11700387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
    Wijermans P; Lübert M
    Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
    Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
    Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.